Tettero, J., Eric, S., Freeman, S., Dillon, R., Cloos, J., Valk, P., Döhner, K., Heuser, M., Röllig, C., Thiede, C., Benner, A., Carota, L., Dall'Olio, D., García, A., Sánchez, A. H., Johnson, S., Lehmann, S., Elicegui, J. M., Mecklenbrauck, R., Metzeler, K., Sobas, M., Thomas, I., Turki, A., Gimenez, L. T., Huntley, B., Russell, N., Versluis, J., Döhner, H., Rivas, J. M. H., Bullinger, L., Ossenkoppele, G. J. (2025). Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials. Blood. https://doi.org/10.1182/blood-2025-343